Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212902 | 1.00 | CCNT1 (0.43) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL1445096 | 0.82 | SCN9A (0.47) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL14844977 | 0.80 | PTPN1 (0.46) | HSP90AA1HSP90AB1CYP3A4TSHRKDM4E | |
| SCHEMBL15618043 | 0.79 | APLNR (0.55) | SYKHSP90AA1PLAUAPLNRCYP1A2 | |
| SCHEMBL24027842 | 0.79 | ALDH1A1 (0.43) | SYKHSP90AA1HSP90AB1NPSR1APLNR | |
| SCHEMBL30212908 | 0.79 | ALDH1A1 (0.43) | SYKHSP90AA1HSP90AB1NPSR1APLNR | |
| SCHEMBL8154563 | 0.76 | CCNT1 (0.52) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL30831604 | 0.76 | CCNT1 (0.52) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL30141974 | 0.76 | CCNT1 (0.52) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL17194883 | 0.75 | CCNT1 (0.43) | CCNT1CCNA2CDK2CDK9CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| EP-4149928-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021229571-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021229571-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | CCNT1 2493/4885CCNA2 3584/4885CDK2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.